Q-omics provides the consensus-scored KCTD10 profile across patient tissues and cancer cell-line models. KCTD10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KCTD10 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, KCTD10 RNA expression shows 20,107 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where KCTD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD10 survival associations across molecular data types. KCTD10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD10 RNA expression–survival associations across cancer types. High KCTD10 expression shows unfavorable associations in BLCA, MESO, LUSC, ACC and LIHC, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for KCTD10 RNA expression.
This table summarizes KCTD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KCTD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD10 shows lower tumor expression in THCA, LUAD, LUSC and KICH and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher KCTD10 RNA expression in tumor versus normal tissue (log2 FC = +0.559, t-test p < 0.001).
This table shows molecular features associated with KCTD10 in patient tissues and cancer cell lines. In patient samples, KCTD10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
